Metagenomi Therapeutics (MGX) Return on Capital Employed (2024 - 2026)
Metagenomi Therapeutics (MGX) posted quarterly Return on Capital Employed of 49.74% for Q1 2026, down 1742.0% year-over-year from 3.03% in Q1 2025, and down 9.61% quarter-over-quarter from 45.38% in Q4 2025.
Metagenomi Therapeutics (MGX) Return on Capital Employed (2024 - 2026) Analysis & Trends
Metagenomi Therapeutics (MGX) has reported Return on Capital Employed for 3 consecutive years, with 49.74% the latest figure, recorded in Q1 2026.
- In Q1 2026, Return on Capital Employed fell 1742.0% year-over-year to 49.74%; the TTM figure through Mar 2026 stood at 49.74% (down 1742.0% YoY), while the FY2025 annual figure was 38.42%, down 950.0% from the prior year.
- Return on Capital Employed retreated to 49.74% in Q1 2026 per MGX's latest filing, from 45.38% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 25.44% in Q2 2024 and bottomed at 49.74% in Q1 2026.
- Historically, Return on Capital Employed has averaged 34.86% across 3 years, with a median of 32.32% in 2025.
- Annual changes were most pronounced in 2025 — Return on Capital Employed tumbled 427 bps — and 2026, when it tumbled 1742 bps.
- Metagenomi Therapeutics' Return on Capital Employed stood at 29.23% in 2024, then tumbled by 55 bps to 45.38% in 2025, then dropped by 10 bps to 49.74% in 2026.
- Business Quant data shows MGX's Return on Capital Employed at 49.74% in Q1 2026, 45.38% in Q4 2025, and 40.03% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.65 Bn | 130.80 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 85.93 Bn | 77.94 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 64.84 Bn | 59.66 Bn | 1.37 Bn | - |
| 4 | Moderna | 57.38 Bn | 52.25 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 41.94 Bn | 36.84 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 31.54 Bn | 28.23 Bn | 992.69 Mn | 26.09% |
| 7 | BioNTech SE | 27.72 Bn | 9.33 Bn | 668.28 Mn | -6.85% |
| 8 | Insmed | 27.49 Bn | 26.33 Bn | 358.27 Mn | -50.93% |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - | 7.88% |
| 10 | Metagenomi Therapeutics | 46.51 Mn | 46.51 Mn | - | -63.77% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -63.77% |
| Mar 31, 2026 | -49.74% |
| Dec 31, 2025 | -45.38% |
| Sep 30, 2025 | -40.03% |
| Jun 30, 2025 | -36.46% |
| Mar 31, 2025 | -32.32% |
| Dec 31, 2024 | -29.23% |
| Sep 30, 2024 | -27.10% |
| Jun 30, 2024 | -25.44% |
| Mar 31, 2024 | -28.05% |